Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
Top Cited Papers
- 1 June 2002
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 359 (9323), 2065-2071
- https://doi.org/10.1016/s0140-6736(02)08938-9
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSFAnnals of Oncology, 2001
- Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492Journal of Clinical Oncology, 2000
- BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.Journal of Clinical Oncology, 1998
- High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMTBone Marrow Transplantation, 1997
- Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registryBone Marrow Transplantation, 1997
- Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytesNature Medicine, 1996
- The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s diseaseAnnals of Oncology, 1995
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDThe New England Journal of Medicine, 1992
- High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease.Journal of Clinical Oncology, 1992